Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
8.71
-0.10 (-1.14%)
Jun 27, 2025, 4:00 PM - Market closed
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Claire Mazumdar Clemon |
Contact Details
Address: 116 Huntington Avenue, Suite 703 Boston, Massachusetts 02116 United States | |
| Phone | 617 468 4219 |
| Website | bicara.com |
Stock Details
| Ticker Symbol | BCAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002023658 |
| CUSIP Number | 055477103 |
| ISIN Number | US0554771032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | Chief Executive Officer and Director |
| Ryan Cohlhepp Pharm.D. | President, Chief Operating Officer and Director |
| Ivan Hyep M.B.A. | Chief Financial Officer |
| Lara S. Meisner J.D. | Chief Legal Officer and Corporate Secretary |
| Rachel Salazar | SVice President of Research & Development Strategy and Operations |
| Sathish Hasige Ph.D. | Senior Vice President and Head of Technical Operations and Supply Chain |
| Dr. David Raben M.D. | Chief Medical Officer |
| Angela Windt | Vice President and Head of Regulatory Affairs |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical and Medical Affairs |
| Jean-Paul Rodrique | Senior Vice President and Global Head of Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2025 | 144 | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 6, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |